The highest prevalence of POT1 alterations has been observed in cutaneous melanoma, non-small-cell lung carcinoma, squamous cell carcinoma, chronic lymphocytic leukemia, and AS (36). This evidence concerns the gene POT1 and non-small cell lung carcinoma.